Muscle-Growth Peptides

What “muscle-growth peptides” actually means

“Muscle-growth peptides” is a search term and a marketing umbrella, not a pharmacological class. The compounds sold under it don’t share a single target, mechanism, evidence base, or legal status — they’re grouped only by what buyers hope they do. Understanding that the label is a wish, not a category, is the most useful thing you can take from this page.

The single most important fact about this group is that almost all of these peptides work indirectly. They don’t add muscle the way the body’s own anabolic machinery does. Instead, most of them nudge the growth-hormone (GH) axis — prompting your pituitary to release a bit more of your own GH, which in turn raises insulin-like growth factor 1 (IGF-1). The promise is that more GH and IGF-1 equals more muscle. As the evidence section below explains, that chain is much weaker than the marketing implies, and its weakest link is the very last step: GH to actual contractile muscle.

Note: This is an educational overview. PeptideHelpUSA does not sell, supply, or prescribe anything, and you will not find dosing numbers or sourcing instructions here — by design. Every compound below is a prescription-only or unapproved substance whose use is a clinical decision, not a purchase.

It’s also worth being blunt up front about what these peptides are not. They are not anabolic steroids, which build muscle directly through the androgen receptor and have decades of human data. They are not SARMs, which are a separate, non-peptide class. The muscle results people associate with steroids do not transfer to this category, and treating them as interchangeable leads to badly miscalibrated expectations.

The compounds people lump together

When you sort the “muscle-growth peptide” universe by how each compound actually works, it splits into five very different buckets.

Growth-hormone secretagogues — the marketed face

This is the largest and most visible group, and it has three sub-families. GHRH analogues mimic growth-hormone-releasing hormone: sermorelin, CJC-1295, and the FDA-approved tesamorelin. GH secretagogues and ghrelin mimetics include ipamorelin and the oral compound ibutamoren (MK-677). GH-releasing peptides (GHRPs) include GHRP-2, GHRP-6, and hexarelin. They differ in half-life and side-effect profile, but they share a mechanism: prompt your own pituitary to release GH in a more pulsatile, “physiologic” pattern than injecting synthetic GH directly. That gentler action is the usual selling point — and also the reason their muscle effect is modest.

Direct growth factors — IGF-1 and “mechano growth factor”

A smaller group skips the GH step and supplies a growth factor directly: IGF-1, its long-acting analogue commonly sold as IGF-1 LR3, and mechano growth factor (MGF / PEG-MGF), an IGF-1 splice variant. On paper these have the strongest anabolic rationale of anything in the category. In practice they are the most dangerous and least legitimate end of it — no approval or compounding pathway, gray-market only, and carrying real concerns about hypoglycemia and the theoretical promotion of abnormal cell growth.

Myostatin-pathway compounds

Myostatin is the body’s natural brake on muscle growth, so “release the brake” compounds — follistatin, myostatin propeptide, and experimental inhibitors in the ACE-031 / ACVR2B family — get marketed for hypertrophy. The reality is sobering: these are highly experimental, some trials were stopped early for safety signals, and none has a legitimate route to a gym bag.

Repurposed recovery peptides — BPC-157 and TB-500

BPC-157 and TB-500 show up constantly in “muscle” stacks, but they belong to the tissue-repair family, not the muscle-building one. Their (largely animal-stage) story is about healing connective tissue and recovering from injury — which can let you train more consistently — not about adding muscle fibers. We treat them properly on the healing and recovery peptides page and in BPC-157 for muscle recovery. Recovery support is real and useful, but it is not hypertrophy, and conflating the two is one of the biggest sources of disappointment in this space.

What isn’t a peptide at all

Plenty of “muscle peptide” lists smuggle in things that aren’t peptides: anabolic steroids, SARMs, clenbuterol, and herbal “natural GH boosters.” Each has its own evidence and legal picture and shouldn’t be reasoned about as if it behaved like a GH secretagogue.

What the evidence actually shows about building muscle

Here is the spine of this whole topic, and it’s uncomfortable for the marketing. The chain these compounds rely on — peptide raises GH, GH raises IGF-1, IGF-1 builds muscle — breaks at the final link in healthy adults.

The cleanest evidence comes from studies of growth hormone itself, given directly, which is a stronger intervention than a secretagogue. Across controlled research in healthy adults, GH reliably increases lean body mass on the scale — but a large share of that gain is fluid and connective tissue, not contractile muscle — while showing little to no consistent improvement in muscle strength or athletic performance, alongside more side effects. If giving GH directly doesn’t dependably translate into stronger, more capable muscle, then a peptide that only coaxes a modest rise in your own GH has an even smaller hill to climb. The “lean mass went up” screenshots people share are real numbers that mostly aren’t what a lifter actually wants.

This matters for expectation-setting. The legitimate, evidenced reasons a clinician might engage the GH axis — documented adult GH deficiency, specific wasting conditions, certain recovery contexts — are narrow and individualized. “I want bigger arms” is not on that list, and no peptide in this category has the human hypertrophy data to put it there. The direct growth factors have better anabolic theory but no safety-vetted human muscle-building evidence and serious downside risk. The myostatin compounds are unfinished science. The repair peptides simply aren’t building agents.

The anti-doping reality every athlete must know

If you compete in anything tested, this section may matter more than all the others combined. The 2026 WADA Prohibited List bans this category about as completely as it bans anything, under section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), and these substances are prohibited at all times — in and out of competition, regardless of dose or route.

The banned list reads like a roster of exactly the compounds above: GHRH and its analogues (CJC-1293, CJC-1295, sermorelin, tesamorelin); GH secretagogues and mimetics (anamorelin, ibutamoren/MK-677, ipamorelin and others); GH-releasing peptides (hexarelin and the GHRP series); and a broad growth-factors clause covering IGF-1 and its analogues, mechano growth factors, and thymosin-β4 / TB-500. Myostatin-modifying agents such as follistatin are prohibited too. In other words, every bucket on this page is covered.

This isn’t a technicality. For NCAA athletes, Olympic-pathway athletes, and competitors in the many professional and amateur bodies that follow the WADA code, a positive test for any of these carries real sanctions — and these compounds are detectable. If you are drug-tested, the practical legal-and-eligibility status of “muscle-growth peptides” is simple: prohibited.

US legal status in 2026 — and why this group fares worse than the headlines

2026 has been a busy regulatory year for peptides, but the headline good news mostly doesn’t apply to the muscle-building compounds. That’s the distinct legal story here.

In April 2026 the FDA removed roughly a dozen peptides from “Category 2” of the interim 503A compounding list, and scheduled its Pharmacy Compounding Advisory Committee (PCAC) to review seven of them on July 23–24, 2026. But look at who’s actually on that docket: BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax, and Epitalon. Those are recovery, cognitive, and longevity compounds. None of the GH secretagogues people buy for muscle are on it. A separate review slated before the end of February 2027 covers GHK-Cu, Melanotan II, LL-37, Dihexa, and PEG-MGF — and GHRP-2 and GHRP-6 are expected to stay restricted entirely.

The two most popular muscle-stack peptides are in an even worse spot. CJC-1295 and ipamorelin had their compounding nominations withdrawn back in 2024 and were voted down by PCAC that year; they are not on the 2026 docket, which leaves their 503A compounding pathway effectively closed for now. Crucially, removal from Category 2 is not approval and not even permission to compound — it only clears a substance to be considered, after which the FDA still has to complete formal rulemaking. This is all very much in motion, not finalized.

A few compound-specific notes round out the picture:

• Sermorelin is the relative bright spot: it has a longer regulatory history and can be compounded by a licensed pharmacy with a valid prescription.
• Tesamorelin (Egrifta) is the only FDA-approved member of the group — but it’s approved for HIV-associated visceral fat accumulation, not muscle building. Its appearance in muscle marketing is off-label.
• IGF-1, IGF-1 LR3, MGF, follistatin and similar have no approval or compounding route. They exist only as gray-market “research-use-only” material, which is not a patient pathway.

For the full chronology and what each status actually means, see the 2026 FDA peptide reclassification, are peptides legal in the US?, and how compounding works under 503A and 503B.

How legitimate access actually works

For the small number of these compounds with any legal route, the path is the same as the rest of legitimate peptide therapy: a licensed provider evaluates you, decides whether intervention is even appropriate, and — where a compound is FDA-approved (tesamorelin) or legally compoundable with a prescription (sermorelin) — issues a prescription that a licensed pharmacy fills, with ongoing monitoring. That’s the entire legitimate menu. “How to get [X]” means a clinical evaluation, not a checkout page. If you’re vetting a provider, how to choose a peptide clinic and peptide quality and safety are the practical next reads.

There is no legitimate access route to IGF-1 LR3, the GHRPs, MGF, or experimental myostatin compounds, because none exists — and that absence is the point, not an obstacle to work around.

The gray-market problem, stated plainly

Because most muscle-growth peptides have no legal supply, the market that does serve them is the unregulated “research chemical” channel: vials of unknown concentration, purity, and even identity, with no pharmacist, no clinician, and no monitoring. Applying a “standard” internet protocol to a product you can’t verify is unsafe regardless of how confident the dose looks, because you don’t actually know what’s in the vial. Combine that with a category whose best-case muscle benefit is modest, whose direct growth factors carry genuine theoretical danger, and whose entire roster is banned in sport, and the risk-to-reward math for self-directed use is poor. If the GH axis genuinely interests you, the version of this worth pursuing is the supervised, evidence-bounded one — not a syringe and a forum post.